GERMLINE BREAST CANCER SUSCEPTIBILITY GENES MUTATION(BRCA) AND EXPRESSION OF PROGRAMMED DEATH LIGAND-1(PDL-1) IN TRIPLE-NEGATIVE BREAST CANCER EGYPTIAN PATIENTS AND CORRELATION WITH CLINICOPATHOLOGICAL CHARACTERISTICS
Ismael, M., Shehata, N., Darwish, A., Elsawy, E., Nakundi Kakonga, V. (2024). GERMLINE BREAST CANCER SUSCEPTIBILITY GENES MUTATION(BRCA) AND EXPRESSION OF PROGRAMMED DEATH LIGAND-1(PDL-1) IN TRIPLE-NEGATIVE BREAST CANCER EGYPTIAN PATIENTS AND CORRELATION WITH CLINICOPATHOLOGICAL CHARACTERISTICS. EKB Journal Management System, 6(1), 20-21. doi: 10.21608/alexpo.2024.264876.1776
Mohamed Farouk Mostafa Ismael; Nashaat Saad Lotfy Shehata; Azza Darwish; Eman Sheta Ali Gawdat Elsawy; Vandrome Nakundi Kakonga. "GERMLINE BREAST CANCER SUSCEPTIBILITY GENES MUTATION(BRCA) AND EXPRESSION OF PROGRAMMED DEATH LIGAND-1(PDL-1) IN TRIPLE-NEGATIVE BREAST CANCER EGYPTIAN PATIENTS AND CORRELATION WITH CLINICOPATHOLOGICAL CHARACTERISTICS". EKB Journal Management System, 6, 1, 2024, 20-21. doi: 10.21608/alexpo.2024.264876.1776
Ismael, M., Shehata, N., Darwish, A., Elsawy, E., Nakundi Kakonga, V. (2024). 'GERMLINE BREAST CANCER SUSCEPTIBILITY GENES MUTATION(BRCA) AND EXPRESSION OF PROGRAMMED DEATH LIGAND-1(PDL-1) IN TRIPLE-NEGATIVE BREAST CANCER EGYPTIAN PATIENTS AND CORRELATION WITH CLINICOPATHOLOGICAL CHARACTERISTICS', EKB Journal Management System, 6(1), pp. 20-21. doi: 10.21608/alexpo.2024.264876.1776
Ismael, M., Shehata, N., Darwish, A., Elsawy, E., Nakundi Kakonga, V. GERMLINE BREAST CANCER SUSCEPTIBILITY GENES MUTATION(BRCA) AND EXPRESSION OF PROGRAMMED DEATH LIGAND-1(PDL-1) IN TRIPLE-NEGATIVE BREAST CANCER EGYPTIAN PATIENTS AND CORRELATION WITH CLINICOPATHOLOGICAL CHARACTERISTICS. EKB Journal Management System, 2024; 6(1): 20-21. doi: 10.21608/alexpo.2024.264876.1776

GERMLINE BREAST CANCER SUSCEPTIBILITY GENES MUTATION(BRCA) AND EXPRESSION OF PROGRAMMED DEATH LIGAND-1(PDL-1) IN TRIPLE-NEGATIVE BREAST CANCER EGYPTIAN PATIENTS AND CORRELATION WITH CLINICOPATHOLOGICAL CHARACTERISTICS

ALEXMED ePosters
Article 1, Volume 6, Issue 1, January 2024, Pages 20-21
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.264876.1776
Authors
Mohamed Farouk Mostafa Ismael1; Nashaat Saad Lotfy Shehata1; Azza Darwish2; Eman Sheta Ali Gawdat Elsawy3; Vandrome Nakundi Kakonga* 1
1Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University
2Department of clinical oncology and nuclear medicine, Faculty of Medicine, Alexandria University
3Department of Pathology, Faculty of Medicine, Alexandria University
Abstract
Triple-negative breast carcinoma (TNBC) is one of the subtypes of breast cancer, known to have a poor prognosis.The most common risk factor is the family history of breast carcinoma, with germline mutation on BRCA1/2 genes being frequently found in comparison to other subtypes. However, non-metastatic TNBC is highly heterogeneous; two subgroups of patients can be described: on the one hand, patients with high-risk disease, not achieving pathological complete response (pCR) despite intense neoadjuvant treatment, and on the other hand, a second group of patients with good prognosis, achieving pCR with less pre-surgery treatment. There is an ongoing effort to de-escalate and escalate therapy, tailoring treatment better to the patients who need it at the right time.
AIM OF THE WORK:
This study aimed to assess the germline BRCA 1/2 mutation and PD-L1 expression in patients with non-metastatic TNBC presented at the Alexandria Clinical Oncology department. It also sought the correlation of the above biomarkerswith the clinicopathological characteristics and the response to neoadjuvant chemotherapy.
Keywords
Triple-negative breast carcinoma (TNBC); GERMLINE BREAST CANCER SUSCEPTIBILITY GENES MUTATION(BRCA); PROGRAMMED DEATH LIGAND-1(PDL-1)
Supplementary Files
Statistics
Article View: 104